Human Mesenchymal Stromal Cell-Derived Extracellular Vesicles Modify Microglial Response and Improve Clinical...

Area of Science:

• Regenerative Medicine
• Neuroscience
• Biotechnology

Background:

• Acute spinal cord injury (SCI) lacks effective clinical interventions for neurological recovery.
• Mesenchymal stromal cells (MSCs) show therapeutic potential for SCI via paracrine signaling, with extracellular vesicles (EVs) being a key mediator.
• Understanding the mechanisms of MSC-derived EVs in SCI is crucial for developing novel therapies.

Purpose of the Study:

• To investigate the efficacy of human MSC-derived EVs (MSCEv) as a cell-free therapy for acute SCI.
• To determine if MSCEv from cytokine-stimulated MSCs exhibit enhanced anti-inflammatory effects post-SCI.
• To evaluate the impact of MSCEv on neuroinflammation and functional recovery in an SCI model.

Main Methods:

• Systemic administration of MSCEv (from naive and stimulated MSCs) in an acute SCI model.
• Immunohistochemical analysis to assess neuroinflammation, including astrocyte and microglia responses.
• Behavioral testing to evaluate locomotor recovery and mechanical sensitivity.

Main Results:

• MSCEv treatment significantly improved locomotor recovery scores in SCI animals.
• A diminished inflammatory response, with astrocyte and microglia disorganization, was observed in MSCEv-treated spinal cord tissue.
• Both naive (MSCEvwt) and stimulated (MSCEv+) MSCEv increased mechanical sensitivity threshold, with MSCEv+ showing a statistically significant greater increase.

Conclusions:

• Systemic administration of MSCEv attenuates neuroinflammation and promotes functional recovery after acute SCI.
• MSCEv represents a viable cell-free therapeutic strategy for SCI, potentially superior to cell-based therapies.
• Stimulating MSCs prior to EV isolation may enhance the therapeutic anti-inflammatory effects of MSCEv.